Experience with isavuconazole in lung transplant recipients with <i>Aspergillus</i> isolation in respiratory tract specimens: A multicenter, observational study.

ABSTRACT:

Background

Aspergillus is a life-threatening opportunistic pathogen in lung transplant recipients (LuTRs). Isavuconazole (ISA) is a broad-spectrum triazole with favorable pharmacokinetics and safety profile. The clinical experience with ISA in LuTRs, however, is still limited.

Methods

We performed an ambispective observational study from June 2019 to June 2024 in 5 Spanish centers. Adult LuTRs with isolation of Aspergillus spp. in respiratory tract specimens and indication of ISA therapy (either for the treatment of invasive pulmonary aspergillosis [IPA] or tracheobronchial aspergillosis [TBA] or for preemptive therapy) were eligible. The safety outcome comprised the occurrence of treatment-emergent adverse events (trAEs) and the need for modification of tacrol

SUBMITTER: Silva JT 

PROVIDER: S-EPMC12671346 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature